BioMarin Pharmaceutical Inc.

Zacks Analyst Blog Highlights: Baker Hughes Inc., NovaMed, Inc., Hewitt Associates Inc., BioMarin Pharmaceutical Inc. and VistaPrint Ltd.

Business Wire (Free subscription) | 30/10/2008

Zacks Analyst Blog Highlights: Baker Hughes Inc., NovaMed, Inc., Hewitt Associates Inc., BioMarin Pharmaceutical Inc. and VistaPrint Ltd. CHICAGO--()--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured...

BioMarin Pharmaceutical Inc. Q3 2008 Earnings Conference Call Transcript

Seeking Alpha China (Free subscription) | 29/10/2008

BioMarin Pharmaceutical, Inc. (BMRN) Q3 FY08 Earnings Call Complete Story »

BioMarin to Present at the Piper Jaffray Healthcare Conference - PR Newswire

Darmstadt (Free subscription) | 26/11/2008

NOVATO, Calif., Nov. 25 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company ...

Data To Be Presented At 58th Annual Meeting Of The American Society Of Human Genetics

Medical News Today (Free subscription) | 07/11/2008

BioMarin Pharmaceutical Inc.

• Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics - PR News Wire

BioMarin to Present at the Credit Suisse Healthcare Conference

Red Orbit (Free subscription) | 05/11/2008

NOVATO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc.

BioMarin Announces Initiation Of Clinical Assessment Program For Morquio A Syndrome

Medical News Today (Free subscription) | 04/11/2008

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced the initiation of the Morquio Clinical Assessment Program (MorCAP) for patients with the lysosomal storage disease Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. MorCAP is designed to augment available data on the disease by measuring endurance and respiratory function and other parameters in affected patients.

Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics

PR News Wire (Free subscription) | 06/11/2008

NOVATO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: ) announced today that data from clinical studies of Kuvan(R) (sapropterin dihydrochloride), Naglazyme(R) (galsulfase) and enzyme replacement therapies for MPS IVA (Morquio Syndrome) and Pompe disease will be presented at the 58th Annual Meeting of the American Society of Human Genetics (ASHG) in Philadelphia, Pennsylvania,...

BioMarin Announces Third Quarter 2008 Financial Results

PR News Wire (Free subscription) | 28/10/2008

... $54 to $69 *Assumes that the $30 million milestone for EU Kuvan approval will be earned in 2008 BioMarin Pharmaceutical Inc. (Nasdaq: ) today announced financial results for the third quarter ended September 30, 2008. Net income was $0.8 million ($0.01 per share) for the third quarter of 2008, compared to a net loss of $5.2 million ($0.05 per share) for the third quarter of 2007....